Abstract: Endocrine Practice 27 (2021) 850e855 Contents lists available at ScienceDirect Endocrine Practice journal homepage: www.endocrinepractice.org Review Article Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy Kristina M. Cross, MS 1, *, Dylan M. Landis, BA 1, Laveena Sehgal, BS 1, J. Drew Payne, DO 2 1 2 School of Medicine, Texas Tech University Health Science Center, Lubbock, Texas Department of Internal Medicine, Texas Tech University Health Science Center, Lubbock, Texas a r t i c l e i n f o a b s t r a c t Article history: Received 31 March 2021 Received in revised form 24 May 2021 Accepted 2 June 2021 Available online 10 June 2021 Objective: To discuss the use of melatonin as an early treatment option on the first day of diagnosis for COVID-19. Methods: Medical Subject Headings terms “COVID-19” and “viral diseases” were manually searched on PubMed, and relevant articles were included. Results: The results showed that melatonin acts to reduce reactive oxygen speciesemediated damage, cytokine-induced inflammation, and lymphopenia in viral diseases similar to COVID-19. Conclusion: These conclusions provide evidence for potential benefits in melatonin use for COVID-19 treatment as early as the day of diagnosis. © 2021 AACE. Published by Elsevier Inc. All rights reserved. Key words: melatonin COVID-19 viral diseases SARS-CoV-2 antioxidant anti-inflammatory agent